金達威(002626.SZ):控股孫公司取得1件發明專利證書
格隆匯6月6日丨金達威(002626.SZ)公佈,公司控股孫公司金達威生物技術和南京樺冠近日收到國家知識產權局頒發的1件發明專利證書,發明名稱:一種吡咯烷酮中間體的合成方法。
本發明涉及藥物中間體合成技術領域,尤其是一種吡咯烷酮中間體的合成方法。應用串聯連續反應技術,將傳統釜式數步反應改進為連續化工藝,解決了傳統釜式反應的放大效應問題,降低了含金屬試劑以及高壓氫化等危險反應的安全風險進而避免了超低温反應釜和高壓氫化釜等設備,提高了生產效率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.